Weekly, high-dose paclitaxel in advanced lung carcinoma-Reference-Cited by-同舟云学术

Weekly, high-dose paclitaxel in advanced lung carcinoma

Published:2003-04-30 Issue:10 Volume:97 Page:2480-2486
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Akerley Wallace,Herndon James E.,Egorin Merrill J.,Lyss Alan P.,Kindler Hedy L.,Savarese Dianne M.,Sherman Carol A.,Rosen D. Marc,Hollis Donna,Ratain Mark J.,Green Mark R.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference18 articles.

1. Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer

2. Phase II Study of Taxol, Merbarone, and Piroxantrone in Stage IV Non-Small-Cell Lung Cancer: The Eastern Cooperative Oncology Group Results

3. Paclitaxel (Taxol)

4. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

5. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer;BioMed Research International;2022-09-13

2. Effect of Menopausal Status on Chemotherapy-Induced Peripheral Neuropathy: Single-Institution Retrospective Audit;Indian Journal of Medical and Paediatric Oncology;2022-02

3. Comparison of Efficacy and Peripheral Neuropathy of Solvent-based Paclitaxel with Paclitaxel Poliglumex and NK105: A Systematic Review and Metaanalysis;Current Pharmaceutical Design;2021-06-17

4. Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO;Clinical Breast Cancer;2020-06

5. Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2019-07